Data Sharing Statement

Travis S, Silverberg MS, Danese S, et al. Vedolizumab for the Treatment of Chronic Pouchitis. N Engl J Med. DOI: 10.1056/NEJMoa2208450.

Question	Authors' Response
Will the data collected for your study	Yes
be made available to others?	
Would you like to offer context for	—
your decision?	
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants' data supporting the results reported in this article, will be made available within 3 months from initial request to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization. Data are available upon request via application at https://search.vivli.org.
When will data availability begin?	Within 3 months from initial request to researchers who provide a methodologically sound proposal
When will data availability end?	—
Will any supporting documents be available?	_
Which supporting documents?	—
Additional information about supporting documents	_
How or where can supporting documents be obtained?	_
When will supporting documents availability begin?	
When will supporting documents availability end?	
To whom will data be available?	To researchers who provide a methodologically sound proposal.

For what type of analysis or purpose?	The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants' data supporting the results reported in this article
By what mechanism?	The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization. Data are available upon request via application at https://search.vivli.org.
Any other restrictions?	—
Additional information	None

This statement was posted on March 30, 2023, at NEJM.org.